CN112433057B - Screening reagent for lupus anticoagulant and preparation method thereof - Google Patents
Screening reagent for lupus anticoagulant and preparation method thereof Download PDFInfo
- Publication number
- CN112433057B CN112433057B CN202011248230.1A CN202011248230A CN112433057B CN 112433057 B CN112433057 B CN 112433057B CN 202011248230 A CN202011248230 A CN 202011248230A CN 112433057 B CN112433057 B CN 112433057B
- Authority
- CN
- China
- Prior art keywords
- reagent
- screening
- lupus anticoagulant
- las
- stability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 121
- 238000012216 screening Methods 0.000 title claims abstract description 106
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 81
- 229940127219 anticoagulant drug Drugs 0.000 title claims abstract description 81
- 206010025135 lupus erythematosus Diseases 0.000 title claims abstract description 81
- 238000002360 preparation method Methods 0.000 title abstract description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 50
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 claims abstract description 27
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 25
- 108010010803 Gelatin Proteins 0.000 claims abstract description 25
- 239000004471 Glycine Substances 0.000 claims abstract description 25
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 25
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 25
- 239000008273 gelatin Substances 0.000 claims abstract description 25
- 229920000159 gelatin Polymers 0.000 claims abstract description 25
- 235000019322 gelatine Nutrition 0.000 claims abstract description 25
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 25
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 23
- 108010014173 Factor X Proteins 0.000 claims abstract description 22
- 239000012190 activator Substances 0.000 claims abstract description 21
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 20
- 102100029117 Coagulation factor X Human genes 0.000 claims abstract description 20
- 239000001110 calcium chloride Substances 0.000 claims abstract description 20
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 20
- 229940105756 coagulation factor x Drugs 0.000 claims abstract description 20
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 18
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 10
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims abstract description 10
- 229940033663 thimerosal Drugs 0.000 claims abstract description 10
- 239000011780 sodium chloride Substances 0.000 claims abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 abstract description 7
- 239000000843 powder Substances 0.000 abstract description 2
- 239000002699 waste material Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 19
- 238000001514 detection method Methods 0.000 description 18
- 210000002381 plasma Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 12
- 239000011593 sulfur Substances 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- 150000003904 phospholipids Chemical class 0.000 description 10
- 238000003908 quality control method Methods 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 206010053567 Coagulopathies Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical group Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- -1 pvc Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 108010074105 Factor Va Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000002607 heparin antagonist Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000002821 viper venom Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of biology, in particular to a screening reagent of lupus anticoagulant and a preparation method thereof. The screening reagent comprises tris (hydroxymethyl) aminomethane, a coagulation factor X activator, rabbit cephalin, gelatin, glycine, trehalose, thimerosal sodium and calcium chloride. The lupus anticoagulant screening kit has good stability and strong anti-interference capability by adjusting the concentration and the components of the stabilizing agent, the reagent can be stabilized for 10 days after being dissolved again at the temperature of 2-8 ℃, and the freeze-dried powder can be stabilized for 2 years after being placed at the temperature of 2-8 ℃. The invention has better stability than the common commercial products, makes full use of the reagent, reduces the reagent waste and saves the cost of the hospital.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a screening reagent of lupus anticoagulant and a preparation method thereof.
Background
Lupus Anticoagulant (LA) is a pathologically circulating anticoagulant, either IgG, igM or a mixture of both. LA blocks the action of activated factor v with prothrombin by recognizing phospholipid binding to prothrombin, inhibits fibrin formation, and interferes with APTT, PT, dRVVT clotting assay in vitro, resulting in prolonged clotting time.
In vivo, LA activates platelets and/or induces pre-thrombotic states by β2-GPI binding, inducing adhesion molecules, tissue factor expression and complement activation, promoting thrombosis. LA acts on vascular endothelial cell membrane phospholipids, interfering with the release of plasminogen activator by endothelial cells to inhibit fibrinolysis; LA acts on platelet membrane phospholipids to interfere with arachidonic acid metabolism and promote platelet activation; LA inhibits endogenous anticoagulant substances associated with phospholipids and enhances blood clotting. About 1/3 of the patients with positive LA tests develop thrombi, and the most common are deep vein thrombosis, pulmonary embolism, and large vessel thrombosis, thrombocytopenia, habitual abortion, stillbirth, and fetal development retardation which are unexplained in obstetrics. Therefore, it is important to provide a reagent for detecting LA.
Detection principle: a screening reagent (LAS) is added into tested blood plasma, a blood coagulation factor X activator directly activates the blood coagulation factor X to become activated blood coagulation factor X, blood is coagulated under the participation of calcium and phospholipid, clotting time is measured, if Lupus Anticoagulant (LA) exists in the blood plasma, the blood plasma clotting time is measured to be beyond a normal reference range, and if the Lupus Anticoagulant (LA) does not exist in the blood plasma, the blood plasma clotting time is measured to be within the normal reference range.
The existing lupus anticoagulant screening reagent has the problem of poor stability, and hemoglobin, bilirubin, triglyceride and heparin in a sample interfere with the accuracy of a detection result.
Disclosure of Invention
In view of the above, the invention provides a screening reagent for lupus anticoagulant and a preparation method thereof. The lupus anticoagulant screening detection reagent (LAS) has the advantages of high stability, strong anti-interference capability on other interfering substances and high sensitivity.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a screening reagent of lupus anticoagulant, which comprises a coagulation factor X activator, rabbit cephalin, buffer solution, gelatin, glycine, trehalose, merosal sodium and calcium chloride;
the screening reagent comprises the following components in percentage by weight:
in the invention, the cephalin in the detection reagent is selected from rabbit cephalin, compared with lecithin, pig cephalin, bovine cephalin, soybean phospholipids, peanut phospholipids, synthetic phospholipids and the like, the rabbit cephalin is matched with other reagents in the screening reagent to ensure that the stability of the screening reagent is stronger, so that the reagent has the characteristics of good stability, long shelf life and the like;
the buffer solution in the detection reagent is Tris-HCl buffer solution, compared with phosphate buffer solution, sodium carbonate-sodium bicarbonate buffer solution, citric acid-sodium citrate buffer solution and HEPES buffer solution, the Tris-HCl buffer solution with pH of 7.4 is matched with other reagents in the screening reagent, so that the stability of the screening reagent is stronger, and the reagent has the characteristics of good stability, long shelf life and the like;
in the prior art, the freeze-drying protective agent and the stabilizer generally comprise saccharides (sucrose, trehalose, lactose, glucose and the like), polymers (polyethylene glycol, pvc, gelatin, polyethyleneimine and the like), amino acids (glycine, arginine, alanine, phenylalanine, threonine, lazy amino acid and the like), and the combination of the gelatin, the glycine and the trehalose is preferably used as the freeze-drying protective agent and the stabilizer, and the stability of the screening reagent is higher after being matched with other reagents in the screening reagent, so that the reagent has the characteristics of good stability, long shelf life and the like;
the preservative in the detection reagent is preferably sodium thimerosal, and compared with the preservatives such as sodium azide, sodium thimerosal, potassium sorbate, sodium lactate and the like, the sodium thimerosal is used as the preservative of the invention, and the stability of the screening reagent is stronger after being matched with other reagents in the screening reagent, so that the reagent has the characteristics of good stability, long shelf life and the like.
Preferably, the screening reagent comprises the following components in percentage by weight:
preferably, the screening reagent comprises the following components in percentage by weight:
more preferably, the screening agent comprises the following components in amounts:
preferably, the screening reagent further comprises water, and the 1L screening reagent comprises the following components in percentage by weight:
preferably, the 1L screening reagent comprises the following components in percentage by weight:
preferably, the amounts of the components in the 1L screening reagent are:
more preferably, the 1L screening reagent comprises the following components in amounts:
the invention provides a preparation method of the screening reagent, which comprises the following steps:
uniformly mixing tris (hydroxymethyl) aminomethane, a coagulation factor X activator, rabbit cephalin, gelatin, glycine, trehalose, thimerosal sodium and calcium chloride;
or, firstly, dissolving the tris (hydroxymethyl) aminomethane in water, then adding the coagulation factor X activator, the rabbit cephalin, the gelatin, the glycine, the trehalose, the thimerosal sodium and the calcium chloride, uniformly mixing, and adjusting the pH to 7.5-8.5.
Preferably, the pH is adjusted to 8.0.
In some embodiments of the invention, the screening agent is prepared by: 2-5 g of tris (hydroxymethyl) aminomethane is weighed and dissolved in 800mL of deionized water, fully stirred for 15-20 min, then 80-100U of coagulation factor X activator, 1.0-1.5 mg of rabbit cephalin, 20-25 g of gelatin, 35-40 g of glycine, 10-15 g of trehalose, 0.1-0.5 g of sulfur Liu Gongna and 1.2-1.8 g of calcium chloride are added, stirring is carried out for 20-50 min, the volume is fixed to 1 liter, the pH value is regulated to 8.0, and the liquid is lupus anticoagulant screening detection reagent (LAS).
The invention also provides a use method of the detection reagent or the kit, wherein the blood plasma to be detected is mixed with the detection reagent in a ratio of 1:1, and the time required for coagulation is measured, so that the lupus anticoagulant screening reagent (LAS) detection time of the blood plasma to be detected is obtained.
The invention provides a screening reagent of lupus anticoagulant and a preparation method thereof. The screening reagent comprises tris (hydroxymethyl) aminomethane, a coagulation factor X activator, rabbit cephalin, gelatin, glycine, trehalose, thimerosal sodium and calcium chloride. Compared with the prior art, the technology has the following advantages:
the lupus anticoagulant screening kit has good stability and strong anti-interference capability by adjusting the concentration and the components of the stabilizing agent, the reagent can be stabilized for 10 days after being dissolved again at the temperature of 2-8 ℃, and the freeze-dried powder can be stabilized for 2 years after being placed at the temperature of 2-8 ℃. The invention has better stability than the common commercial products, makes full use of the reagent, reduces the reagent waste and saves the cost of the hospital.
Detailed Description
The invention discloses a screening reagent of lupus anticoagulant and a preparation method thereof, and the technical parameters can be properly improved by a person skilled in the art by referring to the content of the text. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included in the present invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that variations and modifications can be made in the methods and applications described herein, and in the practice and application of the techniques of this invention, without departing from the spirit or scope of the invention.
The invention provides a reagent (LAS) for screening and detecting lupus anticoagulant, which is prepared from the following raw materials: 2 to 5g of tris (hydroxymethyl) aminomethane, 80 to 100U of coagulation factor X activator, 1.0 to 1.5mg of rabbit cephalin, 20 to 25g of gelatin, 35 to 40g of glycine, 10 to 15g of trehalose, 0.1 to 0.5g of sulfur Liu Gongna, 1.2 to 1.8g of calcium chloride and the balance of deionized water, wherein the final total volume is 1 liter.
The preparation method comprises the following steps: 2-5 g of tris (hydroxymethyl) aminomethane is weighed and dissolved in 800mL of deionized water, fully stirred for 15-20 min, then 80-100U of coagulation factor X activator, 1.0-1.5 mg of rabbit cephalin, 20-25 g of gelatin, 35-40 g of glycine, 10-15 g of trehalose, 0.1-0.5 g of sulfur Liu Gongna and 1.2-1.8 g of calcium chloride are added, stirring is carried out for 20-50 min, the volume is fixed to 1 liter, the pH value is regulated to 8.0, and the liquid is lupus anticoagulant screening detection reagent (LAS).
The manual detection principle of the reagent comprises the following steps: the plasma to be measured was added to the glass tube, after 1min of incubation at 37℃the pre-Wen Ben inventive reagent was added to the plasma, and the time from addition of the reagent to blood clotting was recorded. The reagent is the lupus anticoagulant screening detection reagent (LAS) time of the plasma to be detected.
TABLE 1 methods of use of screening reagents of the invention
The raw materials and the reagents used in the assay reagent and the application thereof and the kit containing the assay reagent can be purchased from the market.
The invention is further illustrated by the following examples:
example 1
2g of tris (hydroxymethyl) aminomethane is weighed and dissolved in 800mL of deionized water, fully stirred for 15-20 min, then 80U of coagulation factor X activator, 1.0mg of rabbit cephalin, 20g of gelatin, 35g of glycine, 15g of trehalose, liu Gongna 0.1.1 g of sulfur and 1.2g of calcium chloride are added, stirring is carried out for 20-50 min, the volume is fixed to 1 liter, the PH is regulated to 8.0, and the solution is lupus anticoagulant screening detection reagent (LAS).
Example 2
3g of tris (hydroxymethyl) aminomethane is weighed and dissolved in 800mL of deionized water, fully stirred for 15-20 min, then 90U of coagulation factor X activator, 1.2mg of rabbit cephalin, 22g of gelatin, 37g of glycine, 10g of trehalose, liu Gongna 0.3.3 g of sulfur and 1.5g of calcium chloride are added, stirring is carried out for 20-50 min, the volume is fixed to 1 liter, the PH is regulated to 8.0, and the solution is lupus anticoagulant screening detection reagent (LAS).
Example 3
5g of tris (hydroxymethyl) aminomethane is weighed and dissolved in 800mL of deionized water, fully stirred for 15-20 min, then 100U of coagulation factor X activator, 1.5mg of rabbit cephalin, 25g of gelatin, 40g of glycine, 14g of trehalose, liu Gongna 0.5.5 g of sulfur and 1.8g of calcium chloride are added, stirring is carried out for 20-50 min, the volume is fixed to 1 liter, the PH is regulated to 8.0, and the solution is lupus anticoagulant screening detection reagent (LAS).
Test example 1A test kit for screening and detecting Lupus Anticoagulant (LAS) of the present invention and a test for comparing the stability of commercial lupus anticoagulant screening and detecting kit (LAS) in open bottle and reconstitution
1. The lupus anticoagulant screening kit (LAS) and the commercial lupus anticoagulant screening kit (LAS) provided in the embodiment 1 of the invention are re-dissolved in the stability under the condition of 2-8 ℃ after being unsealed
The lupus anticoagulant screening kit (LAS) provided in the embodiment 1 of the invention and the commercial lupus anticoagulant screening kit (LAS) are unsealed and redissolved and then stored at 2-8 ℃, and the test is carried out on a Coatron3000 coagulometer with the same normal quality control (35-50 s) every day, and the results are shown in Table 2.
Table 2 comparison of stability of the open-bottle reconstitution with commercial Lupus Anticoagulant (LA) screening reagents
Note that: commercial lupus anticoagulant confirmation reagent consists of Russell viper venom, phospholipid, an anti-heparin agent, calcium, a buffer solution, a stabilizer, sodium azide and a dye.
Table 2 shows that the stability of the lupus anticoagulant screening reagent (LAS) provided by the embodiment 1 of the invention after bottle opening and reconstitution is obviously better than that of the commercial lupus anticoagulant screening reagent (LAS), the lupus anticoagulant screening reagent (LAS) can be stabilized for 10 days after bottle opening and reconstitution, and the commercial lupus anticoagulant screening reagent (LAS) can be placed for about 2 days.
The lupus anticoagulant screening reagent (LAS) prepared in example 2 and example 3 of the present invention was subjected to the above test, and the results were similar to those of the reagent prepared in example 1, with no significant difference.
The stability of the lupus anticoagulant screening reagent (LAS) provided by the invention is obviously improved.
2. Comparison of the accelerated thermal stability at 37 ℃ after the Lupus anticoagulant screening reagent (LAS) and the commercial Lupus anticoagulant screening reagent (LAS) lyophilized powder provided in example 1 of the present invention are reconstituted
The lupus anticoagulant screening reagent (LAS) provided by the embodiment 1 of the invention is stored for continuous measurement at 37 ℃ for 24 hours after being redissolved, the quality control plasma is detected, the result is stable, the commercial lupus anticoagulant screening reagent (LAS) is changed after 8 hours after being redissolved, and the result shows that the lupus anticoagulant screening reagent (LAS) provided by the embodiment 1 of the invention has good stability and long standing time at 37 ℃, and reduces certain cost and expenditure for hospitals. (the results are shown in Table 3).
TABLE 3 accelerated thermal stability contrast test at 37℃after reconstitution of the lupus anticoagulant screening reagent (LAS) and the commercial lupus anticoagulant screening reagent (LAS) of the present invention
The lupus anticoagulant screening reagent (LAS) prepared in example 2 and example 3 of the present invention was subjected to the above test, and the results were similar to those of the reagent prepared in example 2, with no significant difference. The lupus anticoagulant screening reagent (LAS) provided by the invention has the advantages of good stability and long standing time at 37 ℃, and reduces certain cost and expenditure for hospitals.
Test example 2A test for screening and detecting Lupus Anticoagulant (LAS) and a test for comparing interference resistance of a commercial Lupus anticoagulant screening and detecting kit (LAS)
The lupus anticoagulant screening kit (LAS) has high stability and high anti-interference capability by adjusting the concentration and the components of the stabilizing agent, and the result is not affected when the lupus anticoagulant screening kit contains hemoglobin (0-300 mg/dL), bilirubin (0-20 mg/dL), triglyceride (0-800 mg/dL) and heparin (0-300 IU/dL) in a specimen.
TABLE 4 detection results of interference resistance of commercial lupus anticoagulant screening detection kit (LAS)
TABLE 5 anti-interference performance test results of lupus anticoagulant screening kit (LAS) according to example 1 of the present invention
Test example 3 screening of cephalin required for lupus anticoagulant screening reagent (LAS) of the present invention
In the screening reagent of the present invention, the influence of phospholipids of different sources on the stability of the reagent was examined after the selection of other reagent components, and the quality control plasma was examined at 37℃for 20 hours, and the results are shown in Table 6.
TABLE 6 influence of different types of cephalins on stability of Lupus anticoagulant screening reagent (LAC) at 37℃
As can be seen from Table 6, the stability of lupus anticoagulant screening reagents made with rabbit cephalin was far better than those made with phospholipids from other sources.
Test example 4 Effect of stabilizers and lyoprotectants on stability of Lupus anticoagulant screening reagent (LAS)
1. Effect of different classes of polymers on stability of Lupus anticoagulant screening reagents (LAS)
The 1L lupus anticoagulant screening reagent component comprises: under the conditions of 80U of coagulation factor X activator, 1.0mg of rabbit cephalin, 2g of tris (hydroxymethyl) aminomethane, liu Gongna 0.1.1 g of sulfur and 1.2g of calcium chloride, the influence of the addition of polymer substances on the stability of LAS was examined. 3% of polyethylene glycol, pvc, gelatin and polyethyleneimine are respectively added, the mixture is preserved at 37 ℃, and the quality control plasma is detected at fixed time, and the test results are shown in Table 7.
TABLE 7 influence of addition of different classes of polymers at 37℃on the stability of Lupus anticoagulant screening reagents (LAS)
As can be seen from table 7, gelatin has the best stability effect on lupus anticoagulant screening reagents.
2. Effect of different classes of amino acids on stability of Lupus anticoagulant screening reagents (LAS)
The 1L lupus anticoagulant screening reagent component comprises: under the conditions of 80U as a coagulation factor X activator, 1.0mg of rabbit cephalin, 2g of tris (hydroxymethyl) aminomethane, liu Gongna 0.1.1 g of sulfur and 1.2g of calcium chloride, the effect of the addition of amino acids on the stability of LAS was examined. 3% glycine, arginine, phenylalanine, threonine and lysine (hydrochloride) are respectively added, the mixture is preserved at 37 ℃, and the quality control plasma is detected at regular time, and the test results are shown in Table 8.
TABLE 8 influence of addition of different classes of amino acids at 37℃on the stability of Lupus anticoagulant screening reagents (LAS)
As can be seen from table 8, glycine has the best stability effect on lupus anticoagulant screening reagents.
3. Effect of different classes of saccharides on stability of Lupus anticoagulant screening reagents (LAS)
The 1L lupus anticoagulant screening reagent component comprises: under the conditions of 80U as a coagulation factor X activator, 1.0mg of rabbit cephalin, 2g of tris (hydroxymethyl) aminomethane, liu Gongna 0.1.1 g of sulfur and 1.2g of calcium chloride, the effect of adding saccharide on the stability of LAC was examined. 2% of sucrose, trehalose, lactose, glucose and mannitol are respectively added, the mixture is preserved at 37 ℃, and the quality control plasma is detected at regular time, and the test results are shown in Table 9.
TABLE 9 influence of the addition of different classes of sugar substances at 37℃on the stability of Lupus anticoagulant screening reagents (LAS)
As is clear from Table 9, trehalose has an optimal effect on the stability of the lupus anticoagulant screening reagent.
4. Influence of different concentrations of gelatin on stability of lupus anticoagulant screening reagent (LAS)
The 1L lupus anticoagulant screening reagent component comprises: 80U of coagulation factor X activator, 1.0mg of rabbit cephalin, 2g of tris (hydroxymethyl) aminomethane, liu Gongna 0.1.1 g of sulfur and 1.2g of calcium chloride are added, 3% of glycine and 2% of trehalose are added on the basis of the above, and under the condition, 1% -6% of gelatin is added respectively, so that the influence of gelatin concentration on the stability of LAS is studied. LAS was stored at 37℃and the quality control plasma was examined at regular intervals, and the test results are shown in Table 10.
TABLE 10 influence of gelatin content at 37℃on stability of Lupus anticoagulant screening reagent (LAS)
As can be seen from Table 10, the addition of 1 to 5% gelatin to the components of the screening reagent was effective in ensuring that the lupus anticoagulant screening reagent (LAS) was stable at 37℃for 20 hours.
5. Effect of different concentrations of Glycine on stability of Lupus anticoagulant screening Agents (LAS)
The 1L lupus anticoagulant screening reagent component comprises: 80U of coagulation factor X activator, 1.0mg of rabbit cephalin, 2g of tris (hydroxymethyl) aminomethane, liu Gongna 0.1.1 g of sulfur and 1.2g of calcium chloride are added, 2% of trehalose and 1-5% of gelatin (concentration settings: 1%, 2%, 3%, 4% and 5%) are added on the basis of the above, and under the conditions, 1-6% of glycine is added respectively to investigate the effect of glycine concentration on the stability of LAS. LAS was stored at 37℃and the quality control plasma was examined at regular intervals, and the test results are shown in Table 11.
TABLE 11 Effect of Glycine content at 37℃on stability of Lupus anticoagulant screening reagent (LAS)
As can be seen from Table 11, the selective addition of 1-5% glycine to the components of the screening reagent effectively ensured that the lupus anticoagulant screening reagent (LAS) was stable at 37℃for 20 hours.
6. Effect of different concentrations of trehalose on stability of Lupus anticoagulant screening reagent (LAS)
The 1L lupus anticoagulant screening reagent component comprises: 80U of coagulation factor X activator, 1.0mg of rabbit cephalin, 2g of tris (hydroxymethyl) aminomethane, liu Gongna 0.1.1 g of sulfur and 1.2g of calcium chloride are added, and based on the above, 1-5% of glycine (concentration settings: 1%, 2%, 3%, 4% and 5%) and 1-5% of gelatin (concentration settings: 1%, 2%, 3%, 4% and 5%) are added, under the condition, 0.5-4.0% of trehalose are added respectively, and the influence of the trehalose concentration on the stability of LAS is studied. LAS was stored at 37℃and the quality control plasma was examined at regular intervals, and the test results are shown in Table 12.
TABLE 12 Effect of trehalose content on stability of Lupus anticoagulant screening reagent (LAS) at 37℃
As can be seen from Table 12, the addition of trehalose at 0.5% to 3.0% to the components of the above-mentioned confirmation reagent was effective in ensuring that the lupus anticoagulant screening reagent (LAS) was stable at 37℃for 22 hours.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (3)
1. A screening reagent for lupus anticoagulant, which is characterized by comprising a coagulation factor X activator, rabbit cephalin, buffer solution, gelatin, glycine, trehalose, thimerosal sodium and calcium chloride;
the dosage of each component in 1L of the screening reagent is as follows:
2. the method for preparing a screening reagent according to claim 1, comprising the steps of:
uniformly mixing tris (hydroxymethyl) aminomethane, a coagulation factor X activator, rabbit cephalin, gelatin, glycine, trehalose, thimerosal sodium and calcium chloride;
or, firstly, dissolving the tris (hydroxymethyl) aminomethane in water, then adding the coagulation factor X activator, the rabbit cephalin, the gelatin, the glycine, the trehalose, the thimerosal sodium and the calcium chloride, uniformly mixing, and adjusting the pH to 7.5-8.5.
3. The method of claim 2, wherein the pH is adjusted to 8.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011248230.1A CN112433057B (en) | 2020-11-10 | 2020-11-10 | Screening reagent for lupus anticoagulant and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011248230.1A CN112433057B (en) | 2020-11-10 | 2020-11-10 | Screening reagent for lupus anticoagulant and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112433057A CN112433057A (en) | 2021-03-02 |
| CN112433057B true CN112433057B (en) | 2023-06-09 |
Family
ID=74700855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011248230.1A Active CN112433057B (en) | 2020-11-10 | 2020-11-10 | Screening reagent for lupus anticoagulant and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112433057B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105353141A (en) * | 2015-11-17 | 2016-02-24 | 北京美创新跃医疗器械有限公司 | Detection reagent, application thereof and kit containing reagent |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1749536A1 (en) * | 2005-08-03 | 2007-02-07 | Thrombotargets Europe, S.L. | Activated factor X stimulants as new antihemorrhagic agents for topical use |
| CN102692516B (en) * | 2012-06-08 | 2015-01-28 | 上海太阳生物技术有限公司 | Lupus anticoagulant (LA) screening and determining reagent kit (freezing method) |
| US10001495B2 (en) * | 2012-07-25 | 2018-06-19 | Bioverativ Therapeutics Inc. | Blood factor monitoring assay and uses thereof |
| CN107589251B (en) * | 2017-05-19 | 2020-04-28 | 上海原科实业发展有限公司 | Reagent kit for detecting lupus anticoagulant and method for determining presence or absence of lupus anticoagulant |
| CN109444438B (en) * | 2018-10-25 | 2022-03-15 | 宁波瑞源生物科技有限公司 | Stabilizer for APTT detection reagent and APTT detection reagent |
| CN109521204A (en) * | 2018-12-07 | 2019-03-26 | 中国人民解放军陆军军医大学第附属医院 | A kind of lupus anticoagulant detection reagent and preparation method thereof and application method |
-
2020
- 2020-11-10 CN CN202011248230.1A patent/CN112433057B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105353141A (en) * | 2015-11-17 | 2016-02-24 | 北京美创新跃医疗器械有限公司 | Detection reagent, application thereof and kit containing reagent |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112433057A (en) | 2021-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2021581C (en) | Improved stable coagulation controls | |
| EP2722675B1 (en) | Method of measuring blood coagulation time to detect lupus anticoagulants | |
| CN112557665B (en) | Validation reagent for lupus anticoagulant and preparation method thereof | |
| CN108761104A (en) | Coagulation activation agent and its application | |
| JP2011133396A (en) | Activated partial thromboplastin time measuring reagent, activated partial thromboplastin time measuring method, and determination method for determining presence or absence of blood coagulation inhibitor | |
| CN110887970B (en) | Extraction buffer solution, rabbit brain extraction solution, PT detection reagent and PT detection kit | |
| US20110177541A1 (en) | Method for adjusting the coagulation time in calibrator or control plasmas | |
| US20050136499A1 (en) | Control plasma for thrombin activity tests | |
| CN112433057B (en) | Screening reagent for lupus anticoagulant and preparation method thereof | |
| WO2006031387A1 (en) | Thromboplastin reagents | |
| JP5665264B2 (en) | Stable D-dimer liquid formulation | |
| CN107561296A (en) | One kind measure thrombin time（TT）Kit | |
| JP5425062B2 (en) | Method for measuring glycoalbumin and the like using a control sample containing D-mannitol | |
| AU2004239468A1 (en) | Activation mixture | |
| CN115704749A (en) | Kit and preparation method for preparing glycosylated hemoglobin control product | |
| CN115219486B (en) | Detection kit for anti-Xa activity of heparin and low molecular heparin and non-disease diagnosis detection method thereof | |
| US11906532B2 (en) | Hemostasis measurement device quality control formulations | |
| US20140134597A1 (en) | Cellular hemoglobin a1c quality controls | |
| CN107167618A (en) | A kind of lupus anticoagulant detection reagent | |
| CN117949661A (en) | Protein S activity determination kit | |
| CN110133304B (en) | Composition, reagent containing the composition and application thereof | |
| JP3095608B2 (en) | Blood clotting time measurement dry reagent | |
| Wysokinski et al. | Protein C deficiency associated with venous thromboembolism | |
| CN116223821A (en) | Platelet aggregation function detection reagent and application thereof | |
| Mueller et al. | Influence of hydroxyethyl starch (6% HES 130/0.4) administration on hematology and clinical chemistry parameters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |